Centro Hospitalar Do Medio Tejo E.P.E.
- Address
- Avenida Xanana Gusmao 45, 2350-399 Torres Novas, Portugal
Centro Hospitalar Do Medio Tejo E.P.E. - Nephrology and Renal Disease Research Center
Centro Hospitalar Do Medio Tejo E.P.E. is a specialized medical research institution with extensive expertise in nephrology and kidney disease therapeutics. The center demonstrates a strong commitment to advancing treatment options for patients with various forms of renal impairment, from early-stage chronic kidney disease to end-stage renal disease requiring dialysis. Their research portfolio encompasses both innovative pharmacological interventions and cardiovascular outcome studies in vulnerable patient populations.
- Chronic kidney disease progression and therapeutic interventions in diabetic and non-diabetic populations
- End-stage kidney disease (ESKD) management and cardiovascular complications in dialysis patients
- IgA Nephropathy (IgAN) and glomerular disease treatment strategies
- Novel biomarker assessment including proteinuria reduction and inflammatory markers
The center's research initiatives focus on evaluating disease-modifying therapies designed to delay kidney disease progression and reduce proteinuria through various mechanisms of action. Their clinical trial portfolio includes dose-finding studies, placebo-controlled efficacy trials, and long-term safety evaluations. The institution plays a crucial role in advancing treatment paradigms for patients with chronic kidney disease, addressing critical unmet needs in nephrology through participation in multi-phase international trials that assess both renal outcomes and cardiovascular safety profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar Do Medio Tejo E.P.E.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome | Bayer AG | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atrasentan Hydrochloride | 1 | Unknown | 2021-05-19 | 2021-05-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.